SANCUSO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7608282 | CUMBERLAND | Transdermal granisetron |
Jan, 2025
(8 months from now) | |
Sancuso is owned by Cumberland.
Sancuso contains Granisetron.
Sancuso has a total of 1 drug patent out of which 0 drug patents have expired.
Sancuso was authorised for market use on 12 September, 2008.
Sancuso is available in film, extended release;transdermal dosage forms.
Sancuso can be used as use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting.
The generics of Sancuso are possible to be released after 22 January, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NE(NE) | Sep 12, 2011 |
| New Dosage Form(NDF) | Sep 12, 2011 |
Drugs and Companies using GRANISETRON ingredient
Market Authorisation Date: 12 September, 2008
Treatment: Use of granisetron transdermal system to treat/prevent chemotherapy induced nausea and vomiting
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
How can I launch a generic of SANCUSO before it's drug patent expiration?
More Information on Dosage
SANCUSO family patents
